Tesamorelin 10MG

Description

Tesamorelin

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate the pituitary gland to naturally produce and release growth hormone. It features structural modifications that enhance its stability and potency compared to endogenous GHRH. Tesamorelin is primarily researched for its ability to reduce visceral adipose tissue (VAT) and is FDA-approved for the treatment of HIV-associated lipodystrophy. It is also studied for its potential in metabolic health, body composition, and cognitive function.

Key Benefits

• Reduces Visceral Fat: Significantly decreases visceral adipose tissue (VAT), particularly beneficial for abdominal fat accumulation.
• Reduces Liver Fat: Shown to lower hepatic fat content in patients with HIV-associated lipodystrophy.
• Improves Body Composition: Supports increases in lean muscle mass while reducing fat mass.
• Enhances Cognitive Function: May improve memory, executive function, and overall cognition, with research interest in age-related cognitive decline and mild cognitive impairment.
• Metabolic and Cardiovascular Support: Improves lipid profiles (including reduced LDL cholesterol), supports cardiovascular health, and increases IGF-1 levels.
• Exercise Recovery: May accelerate recovery after workouts and improve overall physical performance.

Administration Options

• Subcutaneous (SQ) Injection: The standard and most common method, typically administered into the abdominal fatty tissue.

Note: Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy but is used for broader research purposes in other contexts.

Potential Side Effects

• Common: Injection site reactions (redness, itching, swelling, irritation, or lumps).
• Other Frequent: Muscle aches, spasms, joint pain, insomnia, nausea, or upset stomach.
• Less Common: Mood changes, depression, or fatigue.
• Note: Side effects are often dose-dependent and may improve with continued use or dose adjustment.